Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 15/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.64 |
| ▸ | GAK | O14976 | 3/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.64 |
| ▸ | BUB1 | O43683 | 2/20 | 0.64 |
| ▸ | STK10 | O94804 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | LYN | P07948 | 2/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.64 |
| ▸ | FECH | P22830 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | FLT3 | P36888 | 2/20 | 0.64 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | CIT | O14578 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507566 | 0.94 | FBP1 (0.74) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL1507543 | 0.91 | FBP1 (0.62) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL1507688 | 0.91 | EGFR (0.71) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL1507752 | 0.89 | FBP1 (0.60) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL27368872 | 0.87 | FBP1 (0.66) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL1656960 | 0.86 | FBP1 (0.85) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL1507611 | 0.85 | FBP1 (0.71) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL1507542 | 0.84 | FBP1 (0.65) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL12876988 | 0.84 | FBP1 (0.70) | FBP1EGFRERBB2GAKRIPK2 | |
| SCHEMBL1507537 | 0.82 | EGFR (0.69) | FBP1EGFRERBB2GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | claimed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | claimed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | claimed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | claimed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | claimed |
| JP-2011513427-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2257293-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | Genentech, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | claimed |
| WO-2009111691-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | claimed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | claimed |
| CN-1066142-C | Quinazoline derivatives | PFIZER (US) | 2001-05-23 | — | — | CN | claimed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | claimed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | claimed |
| CN-1137037-A | Quinazoline derivatives | PFIZER (US) | 1996-12-04 | — | — | CN | claimed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | claimed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| EP-1853300-B1 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2013-01-03 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110262436-A1 | TREATMENT METHOD | GENENTECH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011112588-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010120387-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010045344-A1 | COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090209496-A1 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS | OXIGENE, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009103076-A1 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS | OXIGENE, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | ASHKENAZI AVI J | 2009-06-18 | — | — | US | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | FBP1 3954/4885EGFR 1/4885ERBB2 7/4885 |
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | EGFR, ERBB4, TNFRSF9 | FBP1 3954/4885EGFR 1/4885ERBB2 7/4885 |
| US-20090209496-A1 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF RTK INHIBITORS | KDR, EGFR, FLT1 | FBP1 1954/4885EGFR 2/4885ERBB2 6/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | FBP1 2318/4885EGFR 2/4885ERBB2 1/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | FBP1 3954/4885EGFR 1/4885ERBB2 7/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | FBP1 2318/4885EGFR 2/4885ERBB2 1/4885 |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | FBP1 3214/4885EGFR 2/4885ERBB2 3/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | FBP1 3214/4885EGFR 2/4885ERBB2 3/4885 |
| US-20110262436-A1 | TREATMENT METHOD | HGF, HDGF, FGF2 | FBP1 2775/4885EGFR 6/4885ERBB2 26/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | FBP1 3214/4885EGFR 2/4885ERBB2 3/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | FBP1 2489/4885EGFR 129/4885ERBB2 2/4885 |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NOD2, RIPK2, RIPK1 | FBP1 2963/4885EGFR 2498/4885ERBB2 386/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | FBP1 2318/4885EGFR 2/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.